Fezolinetant
Brand names: Veozah · Active ingredient: Fezolinetant
In short: VEOZAH® is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.
What is Fezolinetant used for?
VEOZAH® is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.
⚠ Boxed warning (FDA's strongest warning)
Hepatotoxicity has occurred with the use of VEOZAH in the postmarketing setting (5.1).
•
Perform hepatic laboratory tests prior to initiation of treatment to evaluate for hepatic function and injury. Do not start VEOZAH if either aminotransferase is ≥ 2 x the upper limit of normal (ULN) or if the total bilirubin is ≥ 2 x ULN for the evaluating laboratory.
•
Perform follow-up hepatic laboratory testing monthly for the first 3 months, at 6 months, and 9 months of treatment (2.1, 5.1).
•
Advise patients to discontinue VEOZAH immediately and seek medical attention including hepatic laboratory tests if they experience signs or symptoms that may suggest liver injury (new onset fatigue, decreased appetite, nausea, vomiting, pruritus, jaundice, pale feces, dark urine, or abdominal pain) (2.1, 5.1).
•
Discontinue VEOZAH if transaminase elevations are > 5 x ULN, or if transaminase elevations are > 3 x ULN and the total bilirubin level is > 2 x ULN.
•
If transaminase elevations > 3 x ULN occur, perform more frequent follow-up hepatic laboratory tests until resolution (5.1).
Fezolinetant dosage
Take a single 45 mg VEOZAH tablet orally once daily with or without food.
Take VEOZAH with liquids and swallow whole. Do not cut, crush, or chew tablets.
Administer VEOZAH orally at about the same time each day. If a dose of VEOZAH is missed or not taken at the usual time, administer the missed dose as soon as possible, unless there is less than 12 hours before the next scheduled dose. Return to the regular schedule the following day.
Perform baseline hepatic laboratory tests to evaluate for hepatic function and injury [including serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), serum alkaline phosphatase (ALP), and serum bilirubin (total and direct)] before initiating treatment with VEOZAH. Do not start VEOZAH if ALT or AST is ≥ 2 x ULN or if the total bilirubin is ≥ 2 x ULN for the evaluating laboratory.
While using VEOZAH, perform follow-up hepatic laboratory tests monthly for the first 3 months, at 6 months, and 9 months after initiation of therapy.
Advise patients to discontinue VEOZAH immediately and seek medical attention including hepatic laboratory tests if they experience signs or symptoms that may suggest liver injury .
How to take Fezolinetant — instructions & advice from the label
Advise patients to read the FDA-approved patient labeling (Patient Information).
Evaluation of Hepatic Injury During Treatment with VEOZAH
Inform patients that they will have to have a blood test to evaluate their liver function before beginning VEOZAH and while using VEOZAH monthly for the first 3 months, at 6 months, and 9 months after initialization of therapy. Advise patients to discontinue VEOZAH immediately and seek medical attention including hepatic laboratory tests if they experience signs or symptoms that may suggest liver abnormalities such as new onset fatigue, decreased appetite, nausea, vomiting, pruritus, jaundice, pale feces, dark urine, or abdominal pain .
Serious Adverse Reactions with VEOZAH
Inform patients of possible serious adverse reactions of VEOZAH including hepatic transaminase elevation and liver injury .
Common Adverse Reactions with VEOZAH
Inform patients of possible less serious but common adverse reactions of VEOZAH including abdominal pain, diarrhea, insomnia, back pain, and hot flush .
Drug Interactions
Advise patients to report their use of any other prescription or nonprescription medications or dietary supplements . …
Warnings & precautions
Do not take this medicine if: VEOZAH is contraindicated in women with any of the following conditions:
•Known cirrhosis [see Warnings and Precautions (
5.1), Use in Specific Populations (8.7), and Clinical Pharmacology (12.3)].
•Severe renal impairment or end-stage renal disease .
•Concomitant use with CYP1A2 inhibitors .
In three clinical trials, elevations in serum transaminase [alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)] levels > 3 x the upper limit of normal (ULN) occurred in 2.3% [exposure adjusted incidence rate (EAIR) of 2.7 per 100 person-years] of women receiving VEOZAH and 0.9% (EAIR of 1.5 per 100 person-years) of women receiving placebo. No elevations in serum total bilirubin (> 2 x ULN) occurred. Women with ALT or AST elevations were generally asymptomatic. Transaminase levels returned to pretreatment levels (or close to these) without sequelae with dose continuation, and upon dose interruption, or discontinuation. Women with cirrhosis were not studied .
In the postmarketing setting, cases of drug-induced liver injury with elevations of ALT, AST, alkaline phosphatase (ALP), and total bilirubin occurred within 40 days of starting VEOZAH. Patients reported a general sense of feeling unwell and symptoms of fatigue, nausea, pruritus, jaundice, pale feces, and dark urine. The patients’ signs and symptoms gradually resolved after discontinuation of VEOZAH .
Perform baseline hepatic laboratory tests to evaluate for hepatic function and injury [including serum ALT, serum AST, serum ALP, and serum bilirubin (total and direct)] prior to VEOZAH initiation. Do not start VEOZAH if ALT or AST is ≥ 2 x ULN or if the total bilirubin is ≥ 2 x ULN for the evaluating laboratory.
Perform follow-up hepatic laboratory tests monthly for the first 3 months, at 6 months, and 9 months after initiation of therapy. …
Fezolinetant side effects
The following serious adverse reactions are discussed elsewhere in the labeling:
•Hepatic Transaminase Elevation and Hepatotoxicity .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of VEOZAH was evaluated in three 52-week clinical trials . Across the three clinical trials, a total of 1100 women received VEOZAH. Trials 1 and 2 were placebo-controlled for the first 12 weeks, followed by re-randomization of women previously receiving placebo to VEOZAH (women on VEOZAH remained on VEOZAH) for an additional 40 weeks of uncontrolled treatment. Trial 3 was a randomized, placebo-controlled, double-blind safety study evaluating the safety of VEOZAH for 52 weeks. The adverse reactions reported in at least 2% in VEOZAH 45 mg and greater than placebo in Trial 3 are presented in Table 1.
Adverse Reaction | VEOZAH 45 mg
(n=609)
Total Person-Years=504.2
n (%, EAIREAIR = Number of individuals experiencing an adverse event divided by exposure time (total person-years) x 100.) | Placebo
(n=610)
Total Person-Years=475.0
n (%, EAIR)
Abdominal painAbdominal pain (including Abdominal pain, Abdominal pain lower, Abdominal pain upper). …
Drug interactions
CYP1A2 Inhibitors
VEOZAH is a substrate of CYP1A2. Concomitant use of VEOZAH with drugs that are weak, moderate, or strong CYP1A2 inhibitors, increase the plasma Cmax and AUC of VEOZAH .
VEOZAH is contraindicated in individuals using CYP1A2 inhibitors.
About this medicine
VEOZAH (fezolinetant) is a small-molecule NK3 receptor antagonist.
The chemical name of fezolinetant is (4-Fluorophenyl)[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]methanone having a molecular formula of C16H15FN6OS and a molecular weight of 358.39. The structural formula of fezolinetant is:
Fezolinetant is a white powder. It is very slightly soluble in water (0.29 mg/mL).
Each VEOZAH (fezolinetant) tablet for oral use contains 45 mg of fezolinetant and the following inactive ingredients: ferric oxide, hydroxypropyl cellulose, hypromellose, low-substituted hydroxypropyl cellulose, magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide.
How it works: VEOZAH is a neurokinin 3 (NK3) receptor antagonist that blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron to modulate neuronal activity in the thermoregulatory center. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID cae9f798-24f9-4580-a4fc-e6c710cbda3c. Read the full official label on DailyMed.